Cabozantinib S-Malate
Brand name: Cabometyx
Rank #62 of 500 drugs by total cost
$287.3M
Total Cost
11,285
Total Claims
$287.3M
Total Cost
533
Prescribers
$25K
Cost per Claim
331
Beneficiaries
11,329
30-Day Fills
$539K
Avg Cost/Provider
21
Avg Claims/Provider
About Cabozantinib S-Malate
Cabozantinib S-Malate (sold as Cabometyx) was prescribed 11,285 times by 533 Medicare Part D providers in 2023, costing the program $287.3M. At $25K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 59 | Tofacitinib Citrate (Xeljanz Xr) | $294.4M | 49,478 |
| 60 | Umeclidinium Brm/Vilanterol Tr (Anoro Ellipta) | $294.3M | 480,651 |
| 61 | Gabapentin (Gabapentin) | $291.0M | 15,142,335 |
| 62 | Cabozantinib S-Malate (Cabometyx) | $287.3M | 11,285 |
| 63 | Rsv Vacc, Pref A And Pref B/Pf (Abrysvo) | $284.5M | 872,396 |
| 64 | Bimatoprost (Lumigan) | $284.4M | 610,243 |
| 65 | Apremilast (Otezla) | $283.9M | 59,020 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology